ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1048

Oncostatin M Suppresses Activation of IL-17/Th17 Via Suppressor of Cytokine signaling3 (SOCS3) Regulation in CD4+ T Cells

Young Ok Jung1,2, seon Yeong Lee3, Sung Yeon Lee4, Mi-La Cho3 and Hea-Jin Son5, 1Rheumatology dept, Internal medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, South Korea, 2Rheumatology dept, Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, South Korea, 3Rheumatism Research Center, Catholic Research Institute of Medical Science, Catholic University of Korea, Seoul, South Korea, 4Department of Internal Medicine, Hallym University Sacred Heart Hospital, Gyeonggi-do, South Korea, 5Rheumatism Research Center, Catholic Institutes of Medical Science, The Catholic University of Korea, Seoul, South Korea

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: collagen and interleukins (IL), T cells

  • Tweet
  • Email
  • Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Oncostatin M (OSM) is a pleiotropic cytokine that belongs to the interleukin(IL)-6 group of cytokines. High level of OSM were detected in synoviums of rheumatoid arthritis (RA) patients but its exact role in arthritis perpetuation has not been elucidated. We evaluated the role of OSM in T helper 17(Th17) cell differentiation, the most important cells in arthritis development.

Methods

Collagen-induced arthritis (CIA) was induced in DBA/1J mice. IL-2 immune complex(IC) were injected intraperitoneally three times at 2days intervals before 1st immunization. Severity of arthritis was assessed by clinical scoring of arthritis. CD4+ T cells were isolated by MACS and incubated in Th17 differentiation condition with and without OSM. The levels of cytokines were measured using ELISA. To analyze intracellular cytokine were analyed by FACS. Subpopulations of T cells of spleens were assessed by confocal microscopy. The mRNA levels of OSM and signaling molecules were determined by RT-PCR and real time PCR. The protein levels were assessed by Western blot. Suppressor of cytokine signaling3 (SOCS3) small interfering RNA(siRNA) was transfected by using the Amaxa 4D-nucleofector X unit (Lonxa, Cologne, Germany).

Results

IL-2IC treatment reduced the clinical arthritis score and OSM and SOCS were increased in spleens of IL-21C treated mice. We observed that OSM suppressed Th17 cell differentiation and the levels of IL-17 and IL-21 were decreased in dose dependent manner in vitro. OSM time dependently increase the level of STAT3, STAT5 and SOCS3 in mRNA and protein levels. STA21, the STAT3 inhibitor abrogated the suppressive effect of OSM on Th17 differentiation. SOCS3 siRNA also abrogated the suppressive effect of OSM.

Conclusion

OSM was up-regulated spleens of IL-2IC treated mice. OSM suppressed the Th17cell differentiation and the inhibitory effects of OSM on Th17 cells were via SCOS3 regulation.


Disclosure:

Y. O. Jung,
None;

S. Y. Lee,
None;

S. Y. Lee,
None;

M. L. Cho,
None;

H. J. Son,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/oncostatin-m-suppresses-activation-of-il-17th17-via-suppressor-of-cytokine-signaling3-socs3-regulation-in-cd4-t-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology